Gemcitabine
Back to searchMolecule Structure
Scientific Name
Gemcitabine
Description of the Drug
Gemcitabine is a nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00441
http://www.drugbank.ca/drugs/DB00441
Brand Name(s)
Gemzar
Company Owner(s)
Hameln Rds Gmbh, Actavis Inc, American Regent Inc, Hospira Worldwide, Inc, Emcure Pharmaceuticals Ltd, Fresenius Kabi Usa Llc, Hospira Inc, Novast Laboratories Ltd, Eli Lilly And Co, Accord Healthcare Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA polymerase (alpha/delta/epsilon) | PROTEIN FAMILY | INHIBITOR | CHEMBL2363042 |
| Ribonucleoside-diphosphate reductase RR1 | PROTEIN COMPLEX GROUP | INHIBITOR | CHEMBL2095215 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL4295 | |||||||
| PharmGKB | PA449748 | |||||||
| Human Metabolome Database | HMDB0014584 | |||||||
| DrugBank | DB00441 | |||||||
| PubChem: Thomson Pharma | 15221618 | 15197115 | ||||||
| PubChem | 60750 | |||||||
| LINCS | LSM-5333 | |||||||
| Nikkaji | J357.909C | |||||||
| PDBe | GEO | |||||||
| BindingDB | 429521 | |||||||
| EPA CompTox Dashboard | DTXSID3040487 | |||||||
| DrugCentral | 1283 | |||||||
| Brenda | 40092 | 29312 | 72075 | 154426 | 1899 | 2896 | 153436 | 16928 |
| ChemicalBook | CB4438054 | |||||||
| Guide to Pharmacology | 4793 | |||||||
| rxnorm | GEMCITABINE | INFUGEM | GEMCITABINE HYDROCHLORIDE | GEMZAR | ||||
| KEGG Ligand | C07650 | |||||||
| ChEBI | 175901 | |||||||
| ZINC | ZINC000018279854 |
